Back to Search
Start Over
MiR-23a-3p acts as an oncogene and potential prognostic biomarker by targeting PNRC2 in RCC
- Source :
- Biomedicine & Pharmacotherapy, Vol 110, Iss, Pp 656-666 (2019)
- Publication Year :
- 2018
-
Abstract
- Background Renal cell carcinoma (RCC) is a most common kidney malignancy, with atypical symptoms in the early stage and poor outcome in the late stage. Recently, emerging evidence revealed that some miRNAs play an essential role in the tumorigenesis and progression of RCC. Therefore, the aim of this study is that understand the detailed molecular mechanism of miR-23a-3p in RCC and identify its potential clinical value. Methods In this study, RT-qPCR, wound scratch assay, cell proliferation assay, transwell assay and flow cytometry assay were performed to detect miR-23a-3p expression and its proliferation, migration and apoptosis in RCC. The bioinformatics analysis, RT-qPCR, western blot and luciferase reporter assay were performed to discern and examine the relationship between miR-23a-3p and its potential targets. Moreover, we analyzed the relationship between miR-23a-3p expression and clinicopathological variables or overall survival (OS) from 118 formalin-fixed paraffin-embedded RCC samples. Results miR-23a-3p is significantly up-regulated in RCC tissue samples, RCC cell lines and the TCGA database. Upregulating miR-23a-3p enhances, while silencing miR-23a-3p suppresses cell viability, proliferation and mobility in ACHN and 786-O cell lines. Besides, overexpression of miR-23a-3p inhibits the cell apoptosis. Then our study further reveals that miR-23a-3p regulates tumorigenesis by targeting Proline-Rich Nuclear Receptor Coactivator 2 (PNRC2). Also, the cox proportional hazard regression analysis indicates that low expression of miR-23a-3p patients has a remarkable longer OS. Conclusions Our results reveals that miR-23a-3p may not only serve as a new biomarker for prognosis but also serve as a new therapeutic strategy in the RCC treatment.
- Subjects :
- 0301 basic medicine
PNRC2
Adult
Male
Receptors, Cytoplasmic and Nuclear
RM1-950
Biology
medicine.disease_cause
Flow cytometry
03 medical and health sciences
0302 clinical medicine
Cell Line, Tumor
microRNA
medicine
Biomarkers, Tumor
Gene silencing
Humans
Viability assay
Carcinoma, Renal Cell
Oncogene
Aged
Pharmacology
medicine.diagnostic_test
Cell growth
General Medicine
Oncogenes
Middle Aged
Prognosis
Renal cell carcinoma
Kidney Neoplasms
Survival Rate
MicroRNAs
030104 developmental biology
miR-23a-3p
HEK293 Cells
030220 oncology & carcinogenesis
Cancer research
Trans-Activators
Biomarker (medicine)
Female
Therapeutics. Pharmacology
Carcinogenesis
Biomarkers
Subjects
Details
- ISSN :
- 19506007
- Volume :
- 110
- Database :
- OpenAIRE
- Journal :
- Biomedicinepharmacotherapy = Biomedecinepharmacotherapie
- Accession number :
- edsair.doi.dedup.....f44d953d34bf0272196c21092b92d9df